GoldspireTM Personalized Tumour-Derived Late Stage Clinical Immunotherapy Platform Uses the Full Antigenic Signature of Solid Tumour to Induce Durable Anti-Tumour Immunity
Time: 4:50 pm
day: Day One
Details:
- Goldspire personalized tumour-derived immunotherapy is safe and clinically active in glioblastoma
- Goldspire is active in multiple solid tumour preclinically, induces durable systemic anti-tumour immunity
- Goldspire is currently in late stage clinical development in glioblastoma
